BioOutsource, part of the Sartorius Stedim Biotech Group, opened a new facility in Glasgow.
“Our opening of this new, state-of-the-art facility demonstrates our commitment to our growing list of global customers,” said Gerry MacKay, CEO of BioOutsource, which carries out biologics contract testing and biosimilar characterization. MacKay added that the move doubles the company’s capacity to support the pipeline of biotech and biosimilar products currently in development. Sartorius Stedim Biotech acquired BioOutsource this past April.  BioOutsource officials estimate that in opening and running the new facility, approximately 50 new jobs for scientific and technical professionals will be created in the next six months.

Previous articleEMD Millipore Signs Pegylation Deal with celares
Next articleCells Can Follow a Gene-Flaw-Free Path to Cancer